New Clinical Study Redefines Omega-3 Delivery

A newly published clinical study evaluates omega-3 bonded to phospholipids through Naturmega’s Ruby-O® BPL-O3™ platform. Despite delivering a lower omega-3 dose than standard triglyceride fish oil, Ruby-O® helped significantly more individuals reach healthier triglyceride levels and move out of cardiovascular risk ranges, while also supporting improvements in Omega-3 Index levels.

The findings highlight how molecular structure, specifically omega-3 bonded to phospholipids, can influence absorption and biological effectiveness. This white paper presents the study design, key outcomes, and the commercial implications for nutraceutical brands seeking clinically supported, ready-to-market omega-3 differentiation.

Download here